SCHEMBL426323

SCHEMBL426323

Cc1ccc(N)c(N2CCN(C)CC2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.69
KDM4E B2RXH2 4/20 0.69
GAA P10253 3/20 0.69
MAPK1 P28482 2/20 0.69
HTT P42858 2/20 0.69
PTK2B Q14289 2/20 0.69
RECQL P46063 1/20 0.69
ADRA2C P18825 3/20 0.59
ALDH1A1 P00352 4/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
POLB P06746 1/20 0.53
RAD52 P43351 1/20 0.49
HRH4 Q9H3N8 2/20 0.48
HTR1A P08908 2/20 0.48
HTR3A P46098 2/20 0.48
HSD17B10 Q99714 1/20 0.47
THRB P10828 2/20 0.47
USP2 O75604 1/20 0.47
KMT2A Q03164 2/20 0.44
ALOX15 P16050 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8710759 0.85 ALDH1A1 (0.67) MAPTKDM4EGAAMAPK1HTT
SCHEMBL1339913 0.85 MAPT (0.61) MAPTKDM4EGAAMAPK1HTT
SCHEMBL1339840 0.83 ALDH1A1 (0.65) MAPTKDM4EGAAMAPK1HTT
SCHEMBL13292998 0.81 MEN1 (0.57) MAPTHTTALDH1A1L3MBTL1HTR1A
SCHEMBL4436845 0.81 MAPT (0.46) MAPTKDM4EGAAMAPK1HTT
SCHEMBL20166340 0.80 LGMN (0.67) MAPTKDM4EGAAMAPK1HTT
SCHEMBL18861760 0.80 ALDH1A1 (0.75) MAPTKDM4EGAAMAPK1HTT
SCHEMBL16803397 0.80 KDM4E (0.67) MAPTKDM4EGAAMAPK1HTT
Ammonia Solution, Strong SCHEMBL3580502 0.79 MEN1 (0.55) MAPTHTTALDH1A1L3MBTL1HTR1A
SCHEMBL15597488 0.78 MAPT (0.53) MAPTKDM4EGAAMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642624-B2 Substituted alkylamine derivatives and methods of use AMGEN INC. (US) 2014-02-04 US disclosed
US-20130273004-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2013-10-17 US disclosed
US-8247556-B2 Method for preparing 6-substituted-7-aza-indoles AMGEN INC. (US) 2012-08-21 US disclosed
US-20120065185-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-03-15 US disclosed
US-8058445-B2 Substituted pyridinecarboxamides for the treatment of cancer AMGEN INC. (US) 2011-11-15 US disclosed
US-7687643-B2 Process for preparing 3,3-dimethylindolines AMGEN INC. (US) 2010-03-30 US disclosed
US-7514564-B2 Substituted amine derivatives and methods of use AMGEN INC. (US) 2009-04-07 US disclosed
US-20070185171-A1 Compounds and methods of use AMGEN INC. 2007-08-09 US disclosed
CN-1257892-C New indole derivatives with 5-HT6 receptor affinity HOFFMANN LA ROCHE (CH) 2006-05-31 CN disclosed
CN-1527816-A Novel indole derivatives having 5-HT 6 receptor affinity - 2004-09-08 CN disclosed
WO-1998031669-A1 NOVEL ARYLPIPERAZINE DERIVED FROM PIPERIDINE AS ANTIDEPRESSANT MEDICINES PIERRE FABRE MEDICAMENT (FR) 1998-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130273004-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AADAC, NAT1, PIGO MAPT 4726/4885KDM4E 1013/4885GAA 999/4885
US-20070185171-A1 Compounds and methods of use VHL, PGF, PTGIS MAPT 2988/4885KDM4E 2250/4885GAA 57/4885
US-20120065185-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AADAC, NAT1, PIGO MAPT 4726/4885KDM4E 1013/4885GAA 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.